The community multidisciplinary healthcare provider seeking to improve competence and confidence in the utilization of approved JAK inhibitor therapy and increase their knowledge of emerging treatment options will benefit from this expert review of key data in myelofibrosis from 2019 by Drs. Bose and Mesa. Participants will also be enlightened by how this data can impact their current practice and gain confidence in their ability to communicate with patients to ensure they make informed treatment decisions.

This activity was previously presented as a webinar with live Q&A in January of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

As outcomes for myelofibrosis patients remain suboptimal and treatment options are limited, it is important now more than ever for clinicians to keep abreast of the potential and emerging treatment options. This collaborative peer-to-peer exchange will draw on the collective experience of our three leading experts in research and treatment of patients with myelofibrosis. This activity focuses on the current, newly approved, and emerging JAK inhibitors, including sharing best practices and emerging data from clinical trials.

This activity was previously presented on September 13, 2019 to a live audience during the SOHO 2019 Annual Meeting in Houston, Texas. Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.